Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as Clozapine and Olanzapine.
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.
Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder
- Conditions
- SchizophreniaSchizoaffective Disorder
- First Posted Date
- 2001-07-05
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00018642
- Locations
- 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
Antipsychotic Response in Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2001-07-05
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00018668
- Locations
- 🇺🇸
Department of Veterans Affairs, San Diego, California, United States
CATIE-Alzheimer's Disease Trial
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2001-04-23
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 450
- Registration Number
- NCT00015548
- Locations
- 🇺🇸
VA Medical Center, Coatesville, Pennsylvania, United States
🇺🇸University of California, Irvine Medical Center, Irvine, California, United States
🇺🇸Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States
CATIE- Schizophrenia Trial
- Conditions
- Schizophrenia
- First Posted Date
- 2001-04-09
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 1600
- Registration Number
- NCT00014001
- Locations
- 🇺🇸
Staten Island University Hospital, Staten Island, New York, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Northwestern Medical School Department of Psychiatry, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.